SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of unusually large options trading on Friday. Traders bought 8,964 call options on the stock. This is an increase of 308% compared to the average volume of 2,198 call options.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Anson Funds Management LP acquired a new position in SELLAS Life Sciences Group in the 3rd quarter worth about $992,000. Geode Capital Management LLC increased its position in shares of SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after buying an additional 88,183 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of SELLAS Life Sciences Group during the 3rd quarter worth approximately $78,000. State Street Corp lifted its position in shares of SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after buying an additional 40,500 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Trading Up 7.9 %

Shares of SLS stock opened at $1.06 on Friday. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.72. The stock has a 50 day moving average of $1.07 and a 200 day moving average of $1.16. The stock has a market cap of $74.60 million, a P/E ratio of -1.54 and a beta of 2.41.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.